Exothera, a GMP-certified contract development and manufacturing organisation (CDMO) specialising in viral vectors, RNA therapeutics, and vaccines, has announced the appointment of Cédric Volanti as its new Chief Executive Officer. The appointment, effective 8 October 2024, marks a significant milestone for the Belgian company as it seeks to strengthen its position in the biopharmaceutical manufacturing […]
Fujifilm Irvine Scientific, a provider of cell culture solutions for life science and medical markets, has announced an expansion of its product portfolio through alignment with its sister company, Fujifilm Wako Chemicals U.S.A., Corp. From 1 October 2024, Fujifilm Irvine Scientific will directly promote products from three divisions of Fujifilm Wako Chemicals –Lab Automation, Lab […]
Beckman Coulter, a prominent clinical diagnostics company, and Scopio Labs, a MedTech firm specialising in digital cell morphology solutions, have announced an expansion of their long-term partnership. The new agreement includes global distribution of Scopio’s Full-Field Bone Marrow Aspirate™ (FF-BMA) Application, which is CE-Marked for use with Scopio’s X100 and X100HT scanners.
Beckman Coulter, a clinical diagnostics leader, and Scopio Labs, a medtech company that develops digital cell morphology workflow solutions, today jointly announced expansion of its long-term partnership to include a global distribution agreement of Scopio’s Full-Field Bone Marrow Aspirate™ (FF-BMA) Application. Scopio’s X100 / X100HT with FF-BMA Application are CE-Marked.
Eli Lilly and Company has announced plans for a $4.5 billion (£3.6 billion) facility that integrates pharmaceutical research and manufacturing. The Lilly Medicine Foundry, revealed on 2 October 2024, will aim to streamline drug discovery and production processes. This approach could significantly accelerate the journey from drug development through clinical trials to manufacturing.
New research from the University of Geneva suggests that pancreatic beta cells may function more effectively in isolation, potentially reshaping our understanding of diabetes treatment.
UCSF researchers have developed a novel method to target GTPases, a family of enzymes linked to various diseases including cancer and Parkinson’s, potentially opening new avenues for drug development.
A new study highlights the potential of microbiome-based biomarkers whilst emphasising the need for validated analytical methods and international standards.
ETH Zurich researchers have developed a method to synthesise and test billions of new chemical compounds in weeks, potentially accelerating drug development and expanding the range of treatable conditions.
Researchers at Karolinska Institutet have uncovered key neural processes behind morphine’s analgesic effects, potentially paving the way for safer pain management strategies.
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
